STAR1,211.00

Strides Pharma Science Ltd.

· Pharma & Health
₹ CrorePeersSPARCSUPRIYASHILPAMEDTHYROCARERUBICONVIYASHYATHARTHPARKHOSPSMcap ₹11,162 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth+12.7+6.4
EBITDA Growth+8.0+15.3
EBIT Growth+16.8+18.4
Net Income Growth+3,914.4-84.0
EPS Growth+5,132.7-84.5
Total Assets Growth+3.6+14.5
Total Equity Growth+24.8+21.8
Cash from Operations Growth-2.4+2.7
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.